177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine

Johannes Czernin; Jeremie Calais

doi:10.2967/jnumed.121.262710

Research ArticleEditor's Page

¹⁷⁷Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine

Johannes Czernin and Jeremie Calais

Journal of Nuclear Medicine August 2021, 62 (8) 1025-1026; DOI: https://doi.org/10.2967/jnumed.121.262710

Johannes Czernin

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jeremie Calais

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 62 no. 8 1025-1026

DOI

https://doi.org/10.2967/jnumed.121.262710

PubMed

34330737

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Published online July 30, 2021.

Article Versions

previous version (June 24, 2021 - 15:11).
You are viewing the most recent version of this article.

Author Information

Statistics from Altmetric.com

Cited By...

14 Citations
13 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval

Susan J. Keam

Molecular Diagnosis & Therapy 2022 26 4
Radiolabeled PSMA Inhibitors

Oliver C. Neels, Klaus Kopka, Christos Liolios, Ali Afshar-Oromieh

Cancers 2021 13 24
Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas

Tomas Etrych, Alena Braunova, David Zogala, Lukas Lambert, Nicol Renesova, Pavel Klener

Cancers 2022 14 3
Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T

Lena M. Unterrainer, Leonie Beyer, Mathias J. Zacherl, Franz J. Gildehaus, Andrei Todica, Sophie C. Kunte, Adrien Holzgreve, Gabriel T. Sheikh, Annika Herlemann, Jozefina Casuscelli, Matthias Brendel, Nathalie L. Albert, Vera Wenter, Nina-Sophie Schmidt-Hegemann, Wolfgang G. Kunz, Clemens C. Cyran, Jens Ricke, Christian G. Stief, Peter Bartenstein, Harun Ilhan, Marcus Unterrainer

Biomedicines 2022 10 5
To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy

Sandy Srinivas, Andrei Iagaru

Journal of Nuclear Medicine 2021 62 11
Lutetium-177 radioisotope and therapeutic radiopharmaceuticals: Production, separation and purification, chelation labeling and clinical application

Yujie Miao, Chuanying Liu, Jiuquan Qi, Chengliang Xiao

Chinese Science Bulletin 2024 69 23
SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer—Use of Imaging Agents in Therapeutic Drug Development and Approval

Charlotte Denise Jeffers, Courtney Lawhn-Heath, Regan I. Butterfield, John M. Hoffman, Peter J.H. Scott

Journal of Nuclear Medicine Technology 2022 50 4
Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals

Ulrike Bauder-Wüst, Martin Schäfer, Ruth Winter, Yvonne Remde, Mareike Roscher, Heinz Breyl, Thorsten Poethko, Csaba Tömböly, Martina Benešová-Schäfer

Applied Radiation and Isotopes 2023 197
Current Status and Perspectives of Novel Radiopharmaceuticals with Heterologous Dual-targeted Functions: 2013–2023

Zuojie Li, Qing Ruan, Yuhao Jiang, Qianna Wang, Guangxing Yin, Junhong Feng, Junbo Zhang

Journal of Medicinal Chemistry 2024 67 24
A VISION of ALSYMPCA

Paulo Schiavom Duarte

Journal of Nuclear Medicine 2022 63 2

Article usage

Article usage: June 2021 to April 2025

	Full	Pdf
Jun 2021	0	69
Jul 2021	37	71
Aug 2021	639	268
Sep 2021	216	68
Oct 2021	28	34
Nov 2021	20	24
Dec 2021	11	15
Jan 2022	26	24
Feb 2022	345	44
Mar 2022	301	47
Apr 2022	289	85
May 2022	193	34
Jun 2022	284	39
Jul 2022	360	36
Aug 2022	262	17
Sep 2022	335	32
Oct 2022	237	44
Nov 2022	123	29
Dec 2022	397	18
Jan 2023	392	24
Feb 2023	374	25
Mar 2023	366	20
Apr 2023	284	33
May 2023	201	19
Jun 2023	218	24
Jul 2023	240	16
Aug 2023	348	17
Sep 2023	282	22
Oct 2023	143	11
Nov 2023	167	11
Dec 2023	128	20
Jan 2024	123	16
Feb 2024	222	7
Mar 2024	137	29
Apr 2024	77	23
May 2024	60	14
Jun 2024	64	19
Jul 2024	100	22
Aug 2024	109	17
Sep 2024	58	19
Oct 2024	54	16
Nov 2024	31	25
Dec 2024	34	13
Jan 2025	36	16
Feb 2025	73	17
Mar 2025	54	21
Apr 2025	56	38

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue 8

August 1, 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following 177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

¹⁷⁷Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine

Johannes Czernin, Jeremie Calais

Journal of Nuclear Medicine Aug 2021, 62 (8) 1025-1026; DOI: 10.2967/jnumed.121.262710

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

¹⁷⁷Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine

Johannes Czernin, Jeremie Calais

Journal of Nuclear Medicine Aug 2021, 62 (8) 1025-1026; DOI: 10.2967/jnumed.121.262710

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
- REFERENCES
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer--Use of Imaging Agents in Therapeutic Drug Development and Approval
A VISION of ALSYMPCA
To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy

Google Scholar

Main menu

User menu

Search

¹⁷⁷Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine

Article Information

Article Versions

Author Information

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: June 2021 to April 2025

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles